Can Early B-Type Natriuretic Peptide Assays Predict Symptomatic Patent Ductus Arteriosus in Extremely Low Birth Weight Infants?
- Authors
- Lee, Jang Hoon; Shin, Jeong Hee; Park, Kyu Hee; Rhie, Young Jun; Park, Moon Sung; Choi, Byung Min
- Issue Date
- 2013
- Publisher
- KARGER
- Keywords
- B-type natriuretic peptide; Patent ductus arteriosus; Preterm infant; Predictable usefulness
- Citation
- NEONATOLOGY, v.103, no.2, pp.118 - 122
- Indexed
- SCIE
SCOPUS
- Journal Title
- NEONATOLOGY
- Volume
- 103
- Number
- 2
- Start Page
- 118
- End Page
- 122
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/106519
- DOI
- 10.1159/000343034
- ISSN
- 1661-7800
- Abstract
- Background: Earlier and more accurate identification of a high-risk group of preterm infants that are likely to develop a hemodynamically significant patent ductus arteriosus (hsPDA) would allow specific targeting of early treatment and thus possibly minimize the morbidity and mortality associated with a PDA in extremely low birth weight (ELBW) infants. Objective: To investigate the predictability of B-type natriuretic peptide (BNP) for early targeted treatment of hsPDA in ELBW infants. Methods: 73 ELBW infants that underwent echocardiographic evaluation and plasma BNP measurement after birth were enrolled. 31 infants developed hsPDA (HsPDA group) and 42 infants did not develop hsPDA (nPDA group). Results: BNP levels of the HsPDA group were significantly higher than those of the nPDA group at 24 h of age (921 [318-2,133] vs. 152 [91-450] pg/ml) but not different at 12 h of age. BNP levels at 24 h of age were significantly correlated with the magnitudes of the ductal shunt but not at 12 h of age. The area under the receiver operator characteristic curve of BNP levels for prediction of hsPDA at 24 h of age was 0.830. At the cutoff BNP levels of 200 and 900 pg/ml at 24 h of age, sensitivity was 83.9 and 54.8% and specificity was 61.9 and 95.2%, respectively. Conclusions: BNP levels at 24 h of age can be used as a guide for early targeted treatment of hsPDA and avoid the unnecessary use of cyclooxygenase inhibitors in ELBW infants. Copyright (C) 2012 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.